Johnson & Johnson Hosts 'Shark-Tank'-Like Competition and Crowned This Biotech Startup as Its Winner

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-johnson-johnson.jpg" NAME"Johnson & Johnson Hosts 'Shark-Tank'-Like Competition and Crowned This Biotech Startup as Its Winner" ALT"Johnson & Johnson Hosts 'Shark-Tank'-Like Competition and Crowned This Biotech Startup as Its Winner"April…

Continue ReadingJohnson & Johnson Hosts 'Shark-Tank'-Like Competition and Crowned This Biotech Startup as Its Winner

FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug" ALT"FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug"April…

Continue ReadingFDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug

It's Officially the End of the Road for Massachusetts Biotech Nuclea Biotechnologies

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks-down3.jpg" NAME"It's Officially the End of the Road for Massachusetts Biotech Nuclea Biotechnologiess" ALT"It's Officially the End of the Road for Massachusetts Biotech Nuclea Biotechnologies"April 19, 2017By Mark Terry...…

Continue ReadingIt's Officially the End of the Road for Massachusetts Biotech Nuclea Biotechnologies

Why Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"Why Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant" ALT"Why Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be…

Continue ReadingWhy Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant